Altimmune Inc. (NASDAQ: ALT) announced completion of patient enrollment in its RECLAIM Phase 2 clinical trial evaluating pemvidutide for alcohol ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE